The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman, NL Harris… - Blood, The Journal of the …, 2002 - ashpublications.org
A World Health Organization (WHO) classification of hematopoietic and lymphoid
neoplasms has recently been published. This classification was developed through the …
neoplasms has recently been published. This classification was developed through the …
Cytogenetics of pediatric acute myeloid leukemia: a review of the current knowledge
J Quessada, W Cuccuini, P Saultier, M Loosveld… - Genes, 2021 - mdpi.com
Pediatric acute myeloid leukemia is a rare and heterogeneous disease in relation to
morphology, immunophenotyping, germline and somatic cytogenetic and genetic …
morphology, immunophenotyping, germline and somatic cytogenetic and genetic …
Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies
NI Noguera, G Catalano, C Banella, M Divona… - Cancers, 2019 - mdpi.com
This review highlights new findings that have deepened our understanding of the
mechanisms of leukemogenesis, therapy and resistance in acute promyelocytic leukemia …
mechanisms of leukemogenesis, therapy and resistance in acute promyelocytic leukemia …
Characterization of acute promyelocytic leukemia cases lacking the classic t (15; 17): results of the European Working Party
D Grimwade, A Biondi, MJ Mozziconacci… - Blood, The Journal …, 2000 - ashpublications.org
Acute promyelocytic leukemia (APL) is typified by the t (15; 17), generating the PML-RARα
fusion and predicting a beneficial response to retinoids. However, a sizeable minority of APL …
fusion and predicting a beneficial response to retinoids. However, a sizeable minority of APL …
Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger–Huet anomaly)
K Hoffmann, CK Dreger, AL Olins, DE Olins, LD Shultz… - Nature …, 2002 - nature.com
Pelger–Huët anomaly (PHA; OMIM* 169400) is an autosomal dominant disorder
characterized by abnormal nuclear shape and chromatin organization in blood …
characterized by abnormal nuclear shape and chromatin organization in blood …
VDUP1 upregulated by TGF-β1 and 1, 25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression
SH Han, JH Jeon, HR Ju, U Jung, KY Kim, HS Yoo… - Oncogene, 2003 - nature.com
Vitamin D 3 upregulated protein 1 (VDUP1) is a 1, 25-dihydroxyvitamin D 3 (1, 25 (OH) 2 D
3) upregulated protein, and it is induced by various stresses. In human tumor tissues …
3) upregulated protein, and it is induced by various stresses. In human tumor tissues …
Antigen expression patterns reflecting genotype of acute leukemias
O Hrušák, A Porwit-MacDonald - Leukemia, 2002 - nature.com
Multi-parameter flow cytometry, molecular genetics, and cytogenetic studies have all
contributed to new classification of leukemia. In this review we discuss immunophenotypic …
contributed to new classification of leukemia. In this review we discuss immunophenotypic …
Current views on the genetic landscape and management of variant acute promyelocytic leukemia
X Zhang, J Sun, W Yu, J Jin - Biomarker Research, 2021 - Springer
Acute promyelocytic leukemia (APL) is characterized by the accumulation of promyelocytes
in bone marrow. More than 95% of patients with this disease belong to typical APL, which …
in bone marrow. More than 95% of patients with this disease belong to typical APL, which …
Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia
D Grimwade, F Lo Coco - Leukemia, 2002 - nature.com
Acute promyelocytic leukemia (APL) is characterized by a number of features that underpin
the need for rapid and accurate diagnosis and demand a highly specific treatment approach …
the need for rapid and accurate diagnosis and demand a highly specific treatment approach …
Translocations of the RARα gene in acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) has been recognized as a distinct clinical entity for over
40 years. Although relatively rare among hematopoietic malignancies (approximately 10 …
40 years. Although relatively rare among hematopoietic malignancies (approximately 10 …